Galmed announces new positive data from ongoing armor study open label part showing clinically significant effect on fibrosis improvement

-- updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at aasld late breaker presentations -- -- statistically significant reductions in biomarkers associated with liver fibrosis including alt, ast, fib-4 and proc-3 was also observed in ~ 50 patients -- -- results are an early indication that higher dose of aramchol could provide statistically and clinically meaningful effect on fibrosis in the double-blind placebo controlled regulatory part for submission of an nda under sub-part h-- galmed's management team will host a conference call and webcast to provide an update on current developments with respect to its clinical programs for aramchol™ including nash expert insights on the ongoing open-label part of the armor study, and to discuss financial results for the quarter ended september 30, 2021  today @ 8.30am eastern time tel aviv, israel, nov. 8, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from histology and biomarkers analyses in the ongoing open-label part of the armor phase 3 study.
GLMD Ratings Summary
GLMD Quant Ranking